Serious infections in hospitalized patients frequently require the use of broad-spectrum antimicrobial therapy. Aminoglycosides in combination with other agents traditionally have been used for these infections (8, 12, 17) . However, the toxicity of aminoglycosides and the emergence of resistant nosocomial pathogens can limit their use. The recent development of numerous cephalosporins with expanded spectrums parallels the growing need for alternatives to aminoglycosides. One such agent, cefotaxime (Claforan, HR756; Hoechst-Roussel Pharmaceuticals, Sommerville, N.J.), has been shown to have excellent in vitro activity against Enterobacteriaceae and good activity against grampositive cocci (4, 5, 7, 20, 23) . In vitro activity against strains of Pseudomonas aeruginosa has been comparable to that of ticarcillin, whereas the susceptibility of strains of Bacteroidesfragilis has been variable (2, 4, 14, 22, 25) . Published information regarding the clinical efficacy of cefotaxime is limited. We report our experience with this drug in the therapy of serious infections. 
MATERIALS AND METHODS
Patients were enrolled in the study exclusively through consultation with the Infectious Disease Service of Rush-Presbyterian-St. Luke's Medical Center. Informed consent was obtained from each patient or next of kin. Patients with infections due to multiply resistant strains of Serratia marcescens and patients with granulocytopenia and fever were particularly sought. Cefotaxime was administered to 40 patients; 3 patients received the drug twice. Of 43 courses of therapy, 5 were excluded from analysis. Three of these exclusions resulted when no bacterial pathogen could be isolated. Disseminated infection due to Mycobacterium kansasii and pneumonia due to Aspergillus species, cytomegalovirus, and Herpes simplex virus were present in two such patients. The third patient had pulmonary lymphocytic vasculitis at postmortem examination. No evidence of active infection was found. No antemortem response to broad-spectrum antibiotics was observed. A fourth exclusion was due to the concurrent use of another effective antibiotic with cefotaxime. The final exclusion dealt with a patient who received less than 24 h of therapy. Four of the five excluded cases died; in three cases, the deaths were related to infection.
Thirty-five evaluable patients received 38 courses of therapy. The mean age of patients included in the study was 55.2 years (range, 17 to 88). There were 19 males and 16 females. Associated conditions were present in 32 patients (Table 1) . Of the 38 infections, 29 (MIC) were determined by broth dilution technique with tryptic soy broth (24) . Infections in which organisms were isolated from the blood were deemed bacteremias, irrespective of their source of origin. Infections in which pathogens were exclusively cultured from the urine, bile, or wound exudate were considered urinary tract, biliary, or wound infections, respectively. Infections in which bacteria were grown from bone biopsy cultures were designated osteomyelitis. Nosocomial pneumonias were characterized by fever, purulent sputum production, and new or progressive pulmonary infiltrates acquired 3 or more days after hospital admission. Organisms isolated from expectorated sputa or suctioned secretions from endotracheal tubes were considered pathogens in five such cases. Organisms cultured from lung tissue were considered the etiological agents in another patient. Patients who were febrile, granulocytopenic, and septic on a clinical basis and in whom no pathogen was isolated were classified as having septicemia.
The response of patients to cefotaxime was classified as good, fair, or poor. A good response was defined as clinical improvement with eradication of the pathogen on repeat culture. If no pathogen was isolated from pretreatment cultures, clinical improvement alone was considered a good response to cefotaxime. Clinical improvement was characterized by a decrease in temperature or amelioration of the signs and symptoms of infection. A fair response was defined as clinical improvement with pathogen persistence. Unless otherwise stated, good and fair responses were not associated with relapse. A poor response was defined as a lack of clinical improvement regardless of bacteriological response.
Forty-two courses of therapy were evaluated for toxicity. The patient treated for less than 24 h was excluded from analysis. Parameters assessed before cefotaxime included a complete history, physical examination, blood count, direct and indirect Coombs urinalysis, blood urea nitrogen and serum creatinine, electrolytes, calcium, phosphorus, total protein, albumin, bilirubin, alkaline phosphatase, glutamic oxalacetic transaminase, glutamic pyruvic transaminase, and glucose. These studies were repeated at weekly intervals during and upon completion of the therapy.
RESULTS
Clinical improvement was documented in 25 of 38 courses of therapy (66%). Improvement was independent of daily dose or serum level of cefotaxime. Seventeen courses resulted in a favorable clinical and bacteriological response. One course of therapy effected cure of a nosocomial pneumonia from which no organism was isolated. Five courses of therapy yielded clinical improvement in the absence of a documented site of infection or pathogen. These 23 patients were classified as having good responses to cefotaxime. Two patients exhibited fair responses. These two individuals clinically improved during therapy despite bacteriological failure. Pathogen persistence was documented in sputum and bone, respectively.
Thirteen patients had poor responses to cefotaxime (Table 3 ). In 2 of these 13 clinical failures, the etiological pathogen was eliminated from urine and blood, respectively. However, neither patient responded clinically and both died during therapy. Pathogen persistence was documented in seven failures. In three of the failures, Pseudomonas aeruginosa (two) and Enterococcus (one) resistant to cefotaxime were isolated and required the use of alternative therapies. Two failures with pathogen persistence resulted from an inability to resect infected necrotic tissue. Another such failure occurred in a patient with Serratia marcescens bacteremia after prosthetic aortic valve replacement. De- spite the initial conversion of blood cultures to negative, fever and clinical deterioration progressed during cefotaxime therapy. Additional antibiotics were ineffective in controlling the infection. Antemortem blood cultures were again positive for Serratia marcescens. Patient 7 had persistent Pseudomonas aeruginosa osteomyelitis despite cefotaxime. No pathogen was isolated from four cefotaxime failures. One patient developed fatal sepsis, hypotension, and acute renal failure after surgical repair of an aortoduodenal fistula. Three patients suffered prolonged granulocytopenia and fever, complicating acute nonlymphocytic leukemias. Two of these patients died despite further empiric, broad-spectrum antimicrobial therapy.
Of 35 evaluable patients, 12 died during the study. Nine of 13 cefotaxime failures and 3 of the 25 favorable responders died. Infection was the cause of death in nine patients, which included eight failures and one superinfection.
Cefotaxime was used as the sole initial therapy in the treatment of suspected infection in 14 febrile granulocytopenic patients. One patient received two courses of therapy. All had less than 100 granulocytes per ml of blood. Pathogens were isolated from six patients, of whom four had gram-negative bacteremias, one had VOL. 21, 1982 on October 16, 2017 by guest http://aac.asm.org/ Downloaded from Twenty-three possible complications of cefotaxime were noted in 14 of 42 courses of therapy (Table 4 ). The majority of reactions involved skin and peripheral blood elements. In only two cases were reactions considered severe enough to warrant discontinuation of therapy. Colonic pseudomembranous changes were noted at postmortem examination in two granulocytopenic patients. In one instance, lesions were extensive and may have contributed to the death of the patient. The pathogenesis of the pseudomembranous changes could not be inferred from In vitro susceptibility testing (4, 5, 7, 14, 20, 22, 23, 25, 26) and results obtained in this study suggest that the greatest benefit of cefotaxime might occur in the treatment of multiply resistant, nosocomial, gram-negative pathogens. Fifteen courses of cefotaxime administered for infections caused by multiply resistant Serratia marcescens (13) (15) . The suggestion that the use of antipseudomonal beta-lactam agents may select resistant strains of Pseudomonas aeruginosa is strengthened by our study, in which two of four patients who had received these agents developed fatal Pseudomonas aeruginosa bacteremia resistant to cefotaxime.
The comparative toxicity of cefotaxime versus aminoglycosides may also determine which agents are used in serious gram-negative infections. Of all courses of cefotaxime evaluated in this study, 33% were associated with possible complications of therapy. As has been noted with other cephalosporins, minor hematological and dermatological abnormalities predominated (18, 19) . In 4 of 42 treatment courses, complications necessitated cessation of therapy. A severe pruritic maculopapular rash and a Coombs-positive hemolytic anemia were noted in two such patients. Pseudomonas aeruginosa superinfection and emergence of resistant Pseudomonas aeruginosa during cefotaxime therapy obligated that alternative agents be instituted in the other two patients. The postmortem findings of pseudomembranous enterocolitis in two granulocytopenic patients receiving cefotaxime is noteworthy. Enterocolitis complicating cephalosporin therapy has been infrequently described (1, 11, 13) . However, in one study, 69% of patients with persistent granulocytopenia had pseudomembranous changes noted at autopsy (6) . Nonetheless, patients with diarrhea during cefotaxime therapy should be examined for morpho-VOL. 21, 1982 
